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genotype and the risk of major bleeding in warfarin users. Additionally, interviews 
with local key cardiologists were undertaken. A threshold analysis was performed 
for patients aged 45 years old using the previously constructed decision analytic 
model. The model was populated from the societal perspective. Input data were 
obtained from literature review, meta-analysis, and electronic hospital database 
analyses. Incremental cost-effectiveness ratios (ICERs) were presented as year 2013 
values. Results: Literature search and interviews identified no local evidence on 
the relationship of VKORC1 genotype and the RR of major bleeding in warfarin users. 
In base-case analysis, PGx results in 0.00198 QALY gained, and increases costs by 
2,953.23 THB (98.44 USD) compared with UC (ICER 1,494,707.9 THB [49,823 USD] 
per QALY gained). In order for the PGx test to be cost-effective, the RR for major 
bleeding in VKORC1 variant genotype needs to be shifted from 1.08 (base-case) to 
4.15. ConClusions: Our finding suggests that PGx-guided warfarin dosing is not 
a cost-effective intervention in Thailand due to low likelihood of the RR for major 
bleeding in VKORC1 variant genotype to be as high as 4.15. This evidence can be 
used to assist policy makers and clinicians in efficiently allocating limited resources.
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objeCtives: Rivaroxaban is a new oral anticoagulant subsidised on the Australian 
Pharmaceutical Benefits Scheme (PBS) for prevention of stroke or systemic embolism 
in patients with non-valvular atrial fibrillation or undergoing hip and knee replace-
ment. Recent randomized controlled trials (RCTs) have demonstrated its efficacy 
and safety in treating patients with acute coronary syndrome (ACS). The aim of this 
study was to assess the long-term cost-effectiveness of treating patients with ACS 
with rivaroxaban for a 12 month period and modelling the lifetime costs and ben-
efits from a third party payer perspective. Methods: A two-part decision model 
was constructed to compare treatment with rivaroxaban or current treatment for 
patients with ACS. The first part was a decision-tree model comprising four health 
states (no event, non-fatal MI, non-fatal stroke, death) adopted to simulate treatment 
outcomes based on the event rates reported in the RCTs) health care costs (PBS, 
hospital cost weights) and quality of life weights (from published literature) for 12 
months. Beyond 1-year, treatment outcomes were estimated via a Markov model, with 
lifetime costs, and quality adjusted life years (QALYs) estimated for both arms and an 
Incremental cost-effectiveness ratio (ICER) estimated. A series of sensitivity analyses 
were performed to test the robustness of the result. Results: One-year treatment 
with rivaroxaban was associated with both incremental cost and QALY (AUD 30688 
vs. 30101, 17.51 vs. 17.39 for rivaroxban and placebo respectively) over lifetime horizon 
in the baseline analysis. The ICER of rivaroxaban comparing to placebo was AUD 4896 
per QALY gained. The probabilistic sensitivity analysis varying the event transition 
probability also showed consistent results. ConClusions: Based on clinical and 
health economic evidence, treating ACS patients with rivaroxaban for 12 months was 
associated with an ICER of AUD 4896/QALY, which is below the Willingness-to-pay per 
QALY threshold in Australia inferred from published literature.
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objeCtives: Treatment with the combination of clopidogrel and aspirin taken soon 
after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 
90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown. 
This study sought to estimate the cost-effectiveness of clopidogrel-aspirin regi-
men for acute TIA or minor stroke. Methods: A Markov model was created to 
determine the cost-effectiveness of treatment of acute TIA or minor stroke patients 
with clopidogrel-aspirin compared with aspirin alone. Inputs for the model were 
obtained from clinical trial data, claims databases, and the published literature. The 
main outcome measure was cost per quality-adjusted life-years (QALYs) gained. 
One-way and multivariable probabilistic sensitivity analyses were performed to test 
the robustness of the findings. Results: Compared to aspirin alone, clopidogrel-
aspirin resulted in a lifetime gain of 0.037 QALYs at an additional cost of CNY 1250 
(US$ 192), yielding an incremental cost-effectiveness ratio of CNY 33,800 (US$ 5200) 
per QALY gained. Probabilistic sensitivity analysis showed that clopidogrel-aspirin 
therapy was more cost-effective in 95.7% of the simulations at a willingness-to-pay 
threshold recommended by the World Health Organization of CNY 105,000 (US$ 
16,200) per QALY. ConClusions: Early 90-day clopidogrel-aspirin regimen for acute 
TIA or minor stroke is highly cost-effective in China. If clopidogrel were generic, 
treatment with clopidogrel-aspirin would have been cost saving.
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objeCtives: Non-ST elevation acute coronary syndrome (NSTE-ACS) imposes signifi-
cant health and economic burden to Thai society. Anticoagulants are recommended as 
standard therapy by various clinical practice guidelines. With the advent of a new anti-
coagulant, therefore, this study aimed to determine the cost-effectiveness of fonda-
parinux versus enoxaparin in the treatment of NSTE-ACS in Thailand. Methods: A 
two-part construct model composing of a one-year decision tree and a Markov model 
was developed to capture short and long-term costs and outcomes with the perspec-
tive of provider and society. Effectiveness data were derived from OASIS-5 trial while 
bleeding rates were derived from the Thai Acute Coronary Syndrome Registry (TACSR), 
NT$113,100, and NT$6,556, respectively. The 2nd year average total medical costs 
associated with MI, angina and stroke were NT$63,365, NT$33,469 and NT$52,513, 
respectively. ConClusions: Medical costs associated with cardiovascular diseases 
were substantial to the National Health Insurance program in Taiwan. These results 
indicate potential benefits from interventions aimed at preventing the risk factors of 
cardiovascular diseases such as hypertension, hyperlipidemia, and hyperglycemia.
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objeCtives: We define patients who have not consulted doctors to treat their hyper-
tensions, while they have learned their blood pressure levels are high through health 
check-up, as untreated-hypertension patients. Our research objective is to calculate 
using real world data how much lower the medical cost would be if the untreated-
hypertension patients visit doctors in response to suggestions to do, which represents 
the cost reduction of cost-effectiveness analysis. Methods: We used the data of 
Japan Medical Data Center (JMDC), which provides health insurance claims data with 
linked health check-up data of 1.7 million members from health insurance societies in 
Japan. Results: It is estimated there are around 705 untreated-hypertension patients 
in a virtual (yet supposed-to-be typical according to the JMDC data) health insurance 
society with 10,000 members. They would leave their conditions as they are for an 
average of 6 years knowing that their blood-pressure levels are high. It is necessary to 
advise untreated-hypertension patients to visit doctors for treatment. Such advices 
should be able to start their hypertension treatment in early stages and prevent them 
from future complicating diseases. According to our calculation, the medical cost after 
taking antihypertensive would increase by 11% without aging factors by leaving their 
untreated-hypertension conditions for one year. ConClusions: If the virtual health 
insurance society had all the existing patients with mid-level (160/100 or higher) 
high blood pressures visit doctors right now, their monthly medical cost would be 
0.71 million yen lower against the amount they had to pay in the future (averagely 
in 3 years) if they continue to avoid visiting, which represents 71 yen a month per 
member, and had all the existing patients with mid-level high blood pressures visit 
doctors retrospectively, its monthly medical cost would have been 0.52 million yen 
lower now. This amount represents 52 yen a month per member.
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objeCtives: Acute coronary syndrome (ACS) is a leading cause of morbidity and 
mortality worldwide. This study aims to describe treatment patterns and dis-
ease burden for patients with ACS in Shanghai, China. Methods: A retrospec-
tive descriptive cohort study was conducted. Data were obtained from electronic 
medical records of seven major Shanghai medical centers. Patients who had at least 
one primary diagnosis of ACS between January 2006 and July 2012 were included 
in the study. Patient ACS-related antithrombotic medication use, laboratory tests, 
key comorbidities, health care utilization and direct medical costs were examined. 
Log-linear regression was conducted to explore the factors associated with total 
direct medical cost. Results: A total of 6,601 patients were included with mean 
age of 69.7 (±SD12.5), 73% male and 10% mortality rate. 18.2% of studied patients 
had diabetes as a comorbidity, 21.2% had hypertension, and 8.6% had hyperlipi-
demia. 6,466 (98.0%) of patients had been hospitalized for ACS with mean 14.0 (±16.4) 
days per hospitalization. There were 1,022 patients (15.5%) presented to emergency 
department. Of those, 93.5% received any antithrombotic therapy, including 92.8% 
with antiplatelet agents and 20.8% with anticoagulants. The ACS-related direct 
medical costs were RMB19,421 (±24,741) per hospitalization with medication of 
RMB6,798 and lab tests of RMB1,355, and RMB2,894 (±7,060) per outpatient visit with 
medication of RMB624 and lab tests of RMB464. The higher direct medical cost was 
associated significantly (p< 0.01) with aging, being male, antiplatelet and antico-
agulant uses, diabetes, stroke, hyperlipidemia, hypertension, and chronic kidney 
diseases. ConClusions: Antithrombotic therapeutic treatments were commonly 
used among ACS patients in Shanghai, China. ACS poses significant disease burden 
to the health care system and patients. The higher treatment cost for patients with 
ACS involves antithrombotic use and key comorbidities.
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objeCtives: Our economic evaluation of warfarin pharmacogenetic (PGx) test 
revealed that the test was not cost-effective in Thailand, based on input parameters 
derived from a meta-analysis of Caucasians-dominant studies for the relative risk 
(RR) of major bleeding in variant genotypes of CYP2C9 [2.19, 95%CI (1.33-3.60)] and 
VKORC1 [1.08, 95%CI (0.55-2.10)]. Considering this limitation and the high preva-
lence of VKORC1 variant genotype in Thailand, this study aimed to determine the 
threshold value of the RR of major bleeding for VKORC1 variant genotypes lead-
ing PGx test to be cost-effective. Methods: We conducted a literature search 
for local and international publications investigating the relationship of VKORC1 
